SCHEMBL722258

SCHEMBL722258

COCC(O)Cn1cc(-c2ccnc3cc(-c4cc(OC)c(OC)c(OC)c4)oc23)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
TYK2 P29597 2/20 0.39
JAK3 P52333 2/20 0.39
PDE4C Q08493 3/20 0.38
TTK P33981 2/20 0.37
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
FGFR1 P11362 4/20 0.34
FGFR2 P21802 4/20 0.34
FGFR4 P22455 4/20 0.34
FGFR3 P22607 4/20 0.34
KDR P35968 4/20 0.34
BRD4 O60885 1/20 0.33
PIK3CD O00329 3/20 0.33
PIK3CG P48736 3/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
CYP1A1 P04798 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10266954 0.85 PDE4C (0.42) JAK2JAK1TYK2JAK3PDE4C
SCHEMBL721506 0.84 PDE4C (0.39) PDE4CALDH1A1CYP3A4BRD4CYP1A1
SCHEMBL725161 0.83 PDE4C (0.42) JAK2JAK1TYK2JAK3PDE4C
SCHEMBL724725 0.83 PRKAB2 (0.42) PDE4CALDH1A1CYP3A4CYP1A1CYP1A2
SCHEMBL723668 0.82 PGK1 (0.41) PDE4CBRD4
SCHEMBL722228 0.81 PDE4C (0.43) PDE4CTTKBRD4CYP1A1CYP1A2
SCHEMBL722160 0.81 PDE4C (0.36) PDE4CALDH1A1CYP3A4KDRCYP1A1
SCHEMBL723546 0.80 JAK2 (0.44) JAK2JAK1TYK2JAK3PDE4C
SCHEMBL723093 0.78 PDE4C (0.55) JAK2JAK1TYK2JAK3PDE4C
SCHEMBL725465 0.75 MET (0.39) PDE4CTTKFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB JAK2 14/4885JAK1 25/4885TYK2 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.